These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25260848)

  • 1. Empowering imaging biomarkers of Alzheimer's disease.
    Gutman BA; Wang Y; Yanovsky I; Hua X; Toga AW; Jack CR; Weiner MW; Thompson PM;
    Neurobiol Aging; 2015 Jan; 36 Suppl 1():S69-80. PubMed ID: 25260848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping ventricular expansion onto cortical gray matter in older adults.
    Madsen SK; Gutman BA; Joshi SH; Toga AW; Jack CR; Weiner MW; Thompson PM;
    Neurobiol Aging; 2015 Jan; 36 Suppl 1():S32-41. PubMed ID: 25311280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
    Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feature selective temporal prediction of Alzheimer's disease progression using hippocampus surface morphometry.
    Tsao S; Gajawelli N; Zhou J; Shi J; Ye J; Wang Y; Leporé N
    Brain Behav; 2017 Jul; 7(7):e00733. PubMed ID: 28729939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls.
    Chou YY; Leporé N; Avedissian C; Madsen SK; Parikshak N; Hua X; Shaw LM; Trojanowski JQ; Weiner MW; Toga AW; Thompson PM;
    Neuroimage; 2009 Jun; 46(2):394-410. PubMed ID: 19236926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studying ventricular abnormalities in mild cognitive impairment with hyperbolic Ricci flow and tensor-based morphometry.
    Shi J; Stonnington CM; Thompson PM; Chen K; Gutman B; Reschke C; Baxter LC; Reiman EM; Caselli RJ; Wang Y;
    Neuroimage; 2015 Jan; 104():1-20. PubMed ID: 25285374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diffeomorphometry of regional shape change rates and its relevance to cognitive deterioration in mild cognitive impairment and Alzheimer's disease.
    Tang X; Holland D; Dale AM; Younes L; Miller MI;
    Hum Brain Mapp; 2015 Jun; 36(6):2093-117. PubMed ID: 25644981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
    Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
    Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single time point high-dimensional morphometry in Alzheimer's disease: group statistics on longitudinally acquired data.
    Duchesne S; Valdivia F; Mouiha A; Robitaille N;
    Neurobiol Aging; 2015 Jan; 36 Suppl 1():S11-22. PubMed ID: 25444598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximizing power to track Alzheimer's disease and MCI progression by LDA-based weighting of longitudinal ventricular surface features.
    Gutman BA; Hua X; Rajagopalan P; Chou YY; Wang Y; Yanovsky I; Toga AW; Jack CR; Weiner MW; Thompson PM;
    Neuroimage; 2013 Apr; 70():386-401. PubMed ID: 23296188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition.
    Leow AD; Yanovsky I; Parikshak N; Hua X; Lee S; Toga AW; Jack CR; Bernstein MA; Britson PJ; Gunter JL; Ward CP; Borowski B; Shaw LM; Trojanowski JQ; Fleisher AS; Harvey D; Kornak J; Schuff N; Alexander GE; Weiner MW; Thompson PM;
    Neuroimage; 2009 Apr; 45(3):645-55. PubMed ID: 19280686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DeepAtrophy: Teaching a neural network to detect progressive changes in longitudinal MRI of the hippocampal region in Alzheimer's disease.
    Dong M; Xie L; Das SR; Wang J; Wisse LEM; deFlores R; Wolk DA; Yushkevich PA;
    Neuroimage; 2021 Nov; 243():118514. PubMed ID: 34450261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials.
    Hua X; Hibar DP; Ching CR; Boyle CP; Rajagopalan P; Gutman BA; Leow AD; Toga AW; Jack CR; Harvey D; Weiner MW; Thompson PM;
    Neuroimage; 2013 Feb; 66():648-61. PubMed ID: 23153970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials.
    Hua X; Ching CRK; Mezher A; Gutman BA; Hibar DP; Bhatt P; Leow AD; Jack CR; Bernstein MA; Weiner MW; Thompson PM;
    Neurobiol Aging; 2016 Jan; 37():26-37. PubMed ID: 26545631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects.
    Hua X; Lee S; Yanovsky I; Leow AD; Chou YY; Ho AJ; Gutman B; Toga AW; Jack CR; Bernstein MA; Reiman EM; Harvey DJ; Kornak J; Schuff N; Alexander GE; Weiner MW; Thompson PM;
    Neuroimage; 2009 Dec; 48(4):668-81. PubMed ID: 19615450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease.
    Fjell AM; Walhovd KB; Fennema-Notestine C; McEvoy LK; Hagler DJ; Holland D; Brewer JB; Dale AM;
    J Neurosci; 2010 Feb; 30(6):2088-101. PubMed ID: 20147537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does MRI scan acceleration affect power to track brain change?
    Ching CR; Hua X; Hibar DP; Ward CP; Gunter JL; Bernstein MA; Jack CR; Weiner MW; Thompson PM;
    Neurobiol Aging; 2015 Jan; 36 Suppl 1(0 1):S167-77. PubMed ID: 25444601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Biomarker Combining Imaging and Neuropsychological Assessment for Tracking Early Alzheimer's Disease in Clinical Trials.
    Verma N; Beretvas SN; Pascual B; Masdeu JC; Markey MK;
    Curr Alzheimer Res; 2018 Mar; 15(5):429-442. PubMed ID: 29110613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual rating and volumetric measurement of medial temporal atrophy in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort: baseline diagnosis and the prediction of MCI outcome.
    Varon D; Barker W; Loewenstein D; Greig M; Bohorquez A; Santos I; Shen Q; Harper M; Vallejo-Luces T; Duara R;
    Int J Geriatr Psychiatry; 2015 Feb; 30(2):192-200. PubMed ID: 24816477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.